Hlavičkový papier interný - SVK - Meduni-Wien Aktuell

25Kód štúdie: A6181122 2007-000325-21Žiadateľ: Pfizer SlovakiaPribinova 25, Tower 115811 09 BratislavaSKCentrá:1. NOÚ, Klenova 1, 833 10 Bratislava, MUDr. Tomáš Šálek, PhD.2. Onkologický ústav sv. Alžbety, Heydukova 10, 812 50 Bratislava, prof.MUDr. Stanislav Špánik, PhD.3. NOÚ, Klenova 1, 833 10 Bratislava, MUDr. Jozef Šufliarsky, PhD.............................................................................60A multi-center, randomized, parallel-group, double-blind, placebo-controlled estimation study to assess the efficacy and safety ofmodified release UK-369,003 in the treatment of men with storagelower urinary tract symptoms (LUTS) with and without erectile dysfunction(ED)Kód štúdie: A3711047, 2006-006656-35Žiadateľ: Pfizer Luxembourg SARL, o.z.Pribinova 25811 09 BratislavaSKCentrá:1. FN Martin, Kollárova 2, Urologické oddelenie, 036 59 Martin, prof.MUDr.Ján Kliment, PhD.2. FN L. Pasteura, Rastislavova 43 - pracovisko Trieda SNP 1, Urologickáklinika, 040 11 Košice, prof. MUDr. Jozef Valanský, PhD.3. Nemocnica Ministerstva obrany, Cesta na Červený most 1, Urologickéoddelenie, 833 31 Bratislava, MUDr. Oscar Džurný, PhD.4. Neštátna urologická ambulancia, Piaristická 6, 911 01 Trenčín, MUDr.Roman Sokol............................................................................61A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of inhaled GSK256066 in mild to moderate COPD patientsKód štúdie: IPC101939, 2004-002774-39Žiadateľ: GlaxoSmithKline Slovakia, s.r.o.Galvaniho 7/A821 04 BratislavaSKCentrá:1. FN L. Pasteura, Rastislavova 43, Klinika pneumológie a ftizeológie I.,041 90 Košice, prof. MUDr. Ružena Tkáčová, PhD.2. FNsP Bratislava, Nemocnica Ružinov, Ružinovská 6, Klinika pneumológie aftizeológie I., 826 06 Bratislava, prof. MUDr. Ladislav Chovan, PhD.3. MFN, Kollárova 2, Klinika tuberkulózy a respiračných chorôb, 036 59Martin, prof. MUDr. Eva Rozborilová............................................................................62A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-a therapy